Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
93
-
Total 13F shares, excl. options
-
29.4M
-
Shares change
-
+123K
-
Total reported value, excl. options
-
$84.7M
-
Value change
-
-$205K
-
Put/Call ratio
-
3.95
-
Number of buys
-
41
-
Number of sells
-
-52
-
Price
-
$2.88
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q1 2022
113 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q1 2022.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 93 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.4M shares
of 49.6M outstanding shares and own 59.27% of the company stock.
Largest 10 shareholders include Camber Capital Management LP (4M shares), VANGUARD GROUP INC (3.47M shares), BlackRock Inc. (3.38M shares), MILLENNIUM MANAGEMENT LLC (1.91M shares), Athyrium Capital Management, LP (1.79M shares), RENAISSANCE TECHNOLOGIES LLC (1.77M shares), ACADIAN ASSET MANAGEMENT LLC (1.69M shares), Eversept Partners, LP (1.42M shares), D. E. Shaw & Co., Inc. (1.01M shares), and Kynam Capital Management, LP (653K shares).
This table shows the top 93 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.